💡 Quick Answer
Peptides are legal in the US when you get an FDA-approved one, such as semaglutide, tirzepatide, tesamorelin or PT-141 (bremelanotide), on a prescription. As of November 2026, no unapproved peptide such as BPC-157, TB-500 or ipamorelin is approved to be sold for human use, and FDA treats online vials sold for people as unapproved drugs. On October 30, 2026, HHS published a draft policy saying it will not act against licensed pharmacies that compound six peptides (BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax) on a patient-specific prescription; it is not an FDA approval, and comments close November 13, 2026.
Short answer first: are peptides legal? Some are fully legal prescription drugs, six now have a draft pharmacy route, and the rest have no legal way to be sold for people in the US. Which group a peptide falls into depends on whether the FDA approved it, whether a pharmacy may compound it, where you live, and how it is sold.
Most people asking this have seen the headlines. A 2023 “ban”, a 2026 advisory committee vote, and an HHS policy signed by Robert F. Kennedy Jr. This guide puts those events in date order, gives the status of 12 popular peptides in one table, and covers the UK, Canada, Australia and sport. If you are comparing sellers, see our best legitimate peptide vendors for 2026.
🔑 Key Takeaways
- FDA-approved peptides (semaglutide, tirzepatide, tesamorelin, bremelanotide) are legal with a prescription
- On October 30, 2026, HHS published a draft enforcement discretion policy covering six peptides: BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax
- That policy allows only patient-specific prescriptions from licensed 503A pharmacies, one peptide per product (no blends), and fixed routes; comments close November 13, 2026
- CJC-1295, ipamorelin and DSIP are not covered; DSIP was reviewed in July 2026 and left out
- FDA’s August 24, 2026 warning letters say a lab-only label does not make an online peptide legal when the site shows it is meant for people
- BPC-157 is prescription-only (Schedule 4) in Australia since June 1, 2024, and banned in sport under WADA’s S0 class
Peptide Legal Status in 2026: Peptide-by-Peptide Table
Twelve peptides, four legal positions. Approved prescription drug, compoundable under the HHS draft policy, reviewed but left out, or no legal pharmacy route. Status is as of November 2026.
Sources: Drugs@FDA approval dates (Ozempic NDA 209637, Dec 5, 2017; Wegovy NDA 215256, June 4, 2021; Mounjaro NDA 215866, May 13, 2022; Zepbound NDA 217806, Nov 8, 2023; Egrifta 022505, Nov 10, 2010; Vyleesi NDA 210557, June 21, 2019); HHS policy, Federal Register Oct 30, 2026 and its Appendix A and B; FDA GLP-1 compounding statement; FDA Category 2 list.
Timeline: How US Peptide Rules Changed, 2023–2026
The rules moved four times in three years. Here they are in order, each with its source.
Want the detail behind each step? Our FDA peptide vote breakdown covers the July meeting, the HHS peptide policy explained walks through all ten conditions, and RFK Jr. and the peptide reversal covers the political push that came first.
Understanding Peptide Classification in the US
Peptides aren't a single regulatory category. A peptide can be an approved drug, a compounded drug, an unapproved drug, or, for HGH, something federal law treats on its own terms. Knowing the category is how you know what's legal.
Category 1: FDA-Approved Peptide Medications
Some peptides have completed full clinical trials and received FDA approval as prescription medications. These are fully legal when prescribed by a licensed physician and obtained through a legitimate pharmacy:
Obtaining these without a prescription is illegal. Using them off-label (for purposes not listed in the FDA approval) is legal when prescribed by a physician — off-label prescribing is common and legal in medicine. For the full list, see our FDA-approved peptides list.
Category 2: Unapproved Peptides
Most peptides people talk about online — BPC-157, TB-500, ipamorelin, CJC-1295, GHK-Cu, epitalon and dozens of others — have no FDA approval. That puts them in a specific legal position:
- They cannot legally be sold or marketed as drugs for people without FDA approval
- A licensed pharmacy may compound only bulk ingredients the law allows; as of November 2026 HHS has said it will not act against 503A pharmacies compounding six of them under strict conditions
- Labels such as “lab use only” do not change this when the seller’s site shows the product is meant for people, according to FDA’s 2026 warning letters
- The compounds themselves are not controlled substances (unlike, say, anabolic steroids)
The key distinction: FDA judges the intended use shown by the label, website and marketing, not just the molecule. In its August 24, 2026 letter to one seller, FDA wrote that despite “research use only” labels, “evidence obtained from your website establishes that your products are intended to be drugs for human use,” and it also flagged bacteriostatic water sold for reconstituting them (FDA warning letter 735127).
Category 3: Controlled and Specially Restricted Peptides
A small number of peptide-adjacent compounds carry extra legal restrictions:
- Growth Hormone (HGH): Federal law treats it separately. Under 21 U.S.C. 333(e), knowingly distributing HGH for any use other than an FDA-authorized treatment on a doctor’s order is a felony punishable by up to 5 years in prison (21 U.S.C. 333)
- IGF-1: Not a controlled substance federally but banned in competitive sports
- GH secretagogues (MK-677, etc.): Ibutamoren (MK-677) is in FDA’s Category 2 for both 503A and 503B compounding because a hip-fracture trial “was terminated early due to a potential safety signal of congestive heart failure” (FDA)
Standard peptides like BPC-157, TB-500, and Ipamorelin are not controlled substances. This is an important distinction that gets confused frequently.
The FDA's 2023–2026 Actions: What Actually Changed
Three years, three big moves. Here's what actually happened — and what didn't.
What Happened: Compounding Pharmacy Restrictions
In September 2023 (September 29 for most of them), FDA placed BPC-157, TB-500, epitalon, KPV, MOTS-c, Semax and several other peptides, including ipamorelin, in “Category 2”, its list of bulk substances that may present significant safety risks. Pharmacies took that as a stop sign, and people who had been getting peptides through their doctor and a compounding pharmacy lost that route.
What many articles missed: these peptides were never on the 503A bulks list in the first place. HHS’s October 2026 policy says that neither going onto Category 2 nor coming off it on April 22, 2026 changed their legal status for compounding (HHS policy, Appendix B).
What Didn't Happen: Online Peptide Sales Did Not Become Legal
Gray-market sellers kept selling with lab-only labels, and many readers assumed that made the sale legal. It does not. FDA sent warning letters to online peptide sellers on February 26, 2025, March 31, 2026 and August 24, 2026, each calling the products unapproved new drugs under section 505(a) of the FD&C Act despite those labels (example letter).
The Current Situation (November 2026)
As of November 2026, the peptide regulatory environment looks like this:
- FDA-approved peptides remain available through pharmacies with a prescription
- Six peptides (BPC-157, TB-500, KPV, MOTS-c, epitalon, Semax) have a draft 503A pharmacy route under HHS’s October 30, 2026 policy, with comments open until November 13, 2026
- Compounded semaglutide and tirzepatide are tightly limited again: FDA declared both shortages over (tirzepatide December 19, 2024; semaglutide February 21, 2025), and on April 1, 2026 confirmed neither is on the 503B bulks list or the shortage list (FDA)
- Online sellers using lab-only labels continue to receive FDA warning letters
- Some states have introduced their own regulations (more on this below)
For practical advice on where to buy, see our where to buy peptides guide.
What the October 2026 HHS Policy Does and Doesn't Do
It is a promise not to enforce, not a change in the law. HHS says it “does not intend to take enforcement action” against a state-licensed pharmacy, federal facility or licensed physician compounding a peptide in its Appendix A, while FDA writes rules for the 503A bulks list (Federal Register 2026-22192). The notice says the policy “is not binding on HHS or the public” and that HHS may revisit it if a safety signal or quality problem appears.
- Prescription only: each product needs a valid patient-specific prescription
- One peptide per product: the compounded drug may contain only a single active ingredient from Appendix A, so stacks and blends are outside the policy
- Fixed routes: BPC-157 by injection, mouth or skin; TB-500 and MOTS-c by injection; epitalon by injection in intermittent courses; KPV oral and topical; Semax intranasal only
- Tested ingredient: raw material from an FDA-registered manufacturer with a valid certificate of analysis
- Reporting and labeling: serious adverse events go to FDA MedWatch, and the label must read “This is a compounded drug product. Not for resale.”
Are Peptides Legal in the UK, Canada and Australia? (By Country)
Peptide legality varies enormously by jurisdiction. Here's the current status in major markets:
United States: Where the Line Sits
The US gives the widest legal access among major Western countries, but only through a doctor. Approved peptides need a prescription, and the six HHS peptides need a prescription filled by a 503A pharmacy. Buying lab-labeled vials online sits outside both routes. FDA’s published enforcement in 2025–2026 has targeted sellers through warning letters rather than individual buyers.
Australia: The Strictest Approach
Australia regulates peptide products as therapeutic goods through the TGA (Therapeutic Goods Administration). BPC-157 became a Schedule 4 (prescription-only) substance on June 1, 2024, with an Appendix D entry that makes possession without authority illegal; the change followed 48 import referrals since July 2022 (TGA final decision). The TGA’s April 13, 2026 safety advisory adds that people importing unapproved peptides need a prescription where one is required, and that unlabelled or code-labelled vials will not be released (TGA).
United Kingdom: Unlicensed Medicines
The UK treats peptides sold for health effects as medicines. You cannot legally sell them without a Medicines and Healthcare products Regulatory Agency (MHRA) licence. On 28 May 2026 the MHRA raided a site near Northampton that it says was making unlicensed weight-loss medicines, including retatrutide and tirzepatide, “as well as peptide products”, seized around 12,000 doses and arrested two people under the Human Medicines Regulations 2012 (MHRA).
Canada: Unauthorized Drugs
Health Canada’s April 9, 2026 public advisory says unauthorized drug products “are illegal in Canada” and that lab-only labelling does not make them legal or exempt from the rules. Its list of seized injectable peptides includes BPC-157, CJC-1295, DSIP, epitalon, GHK-Cu, ipamorelin, KPV, MOTS-c, SS-31, TB-500 and retatrutide (Health Canada). Authorized drugs carry an 8-digit Drug Identification Number (DIN).
Peptide Therapy Through a Doctor
The most straightforward legal route to peptide therapy is through a licensed physician. In 2026 that route got wider: approved peptides are prescribed as usual, and six unapproved peptides can now be compounded by a 503A pharmacy under HHS’s draft policy. For a complete overview of the medical route, see our peptide therapy guide.
How to Find a Peptide-Knowledgeable Doctor
- Anti-aging / longevity clinics: These specialize in peptide therapy and are the most common pathway
- Functional medicine doctors: Many are trained in peptide protocols
- Telemedicine platforms: Several telehealth services now offer peptide consultations and prescriptions
- Sports medicine physicians: Some are knowledgeable about healing peptides like BPC-157 and TB-500
What Can Doctors Still Prescribe?
Physicians can prescribe FDA-approved peptides (semaglutide, tirzepatide, tesamorelin, bremelanotide) on or off label. As of November 2026 they can also send a patient-specific prescription for BPC-157, TB-500, KPV, MOTS-c, epitalon or Semax to a 503A pharmacy that meets HHS’s conditions, one peptide per product. CJC-1295, ipamorelin and DSIP have no such route. Ask the pharmacy whether it follows the HHS conditions before you pay.
Are Peptides Banned in Sport?
Yes, most of them. If you compete in tested sports, the rules are stricter than the law. WADA’s 2026 Prohibited List, in force since January 1, 2026, bans the peptides used most often (WADA):
WADA-Banned Peptides
- All GH secretagogues (Ipamorelin, CJC-1295, GHRP-2, GHRP-6, MK-677, etc.)
- All growth hormone releasing hormone analogs (Sermorelin, Mod GRF 1-29)
- BPC-157, named by WADA under S0 (non-approved substances), prohibited at all times
- TB-500 (Thymosin Beta-4) — banned as a growth factor
- GHK-Cu — currently not explicitly banned but potentially prohibited under the catch-all growth factor category
- IGF-1 and all analogs
If you're subject to WADA testing (Olympic sports, professional athletics, NCAA, etc.), assume most peptides are prohibited. S0 is a catch-all: any drug with no approval for human therapeutic use is banned even if WADA does not name it. Being caught with these compounds can result in multi-year suspensions regardless of whether they provided a competitive advantage.
Is It Legal to Buy Peptides Online?
It depends on what you buy and from whom. An FDA-approved peptide bought from a licensed online pharmacy on your prescription is legal. A compounded BPC-157 or TB-500 prescription filled by a licensed 503A pharmacy fits HHS’s draft policy. A vial bought from a website that labels it “lab use only” and ships it with bacteriostatic water is, in FDA’s view, an unapproved drug sold illegally by the seller.
FDA’s published enforcement falls on the seller, not the buyer. The practical risks for a buyer are different: no guarantee of what is in the vial, no recourse if it is wrong, and possible customs seizure on imports.
How to Buy Peptides Legally: Practical Guide
The Online Vendor Route: What to Check
Many people still buy unapproved peptides from online vendors. That is outside the prescription routes above, so if you go this way, quality checks are all you have.
What to look for in a vendor:
- No therapeutic claims: A legitimate vendor won't say "cures tendon injuries" or "lose 20 lbs" — they sell the compound, not health claims
- Third-party COAs: Certificates of analysis from independent labs (not just in-house testing)
- US-based operations: Easier legal accountability and recourse
- Transparent contact information: Real business address, phone number, customer support
- Batch numbers that match the COA: The lot on your vial should match the lot on the test report
Our cheapest places to buy peptides guide covers pricing comparisons across vetted vendors.
The Prescription Route
For FDA-approved peptides (semaglutide, tirzepatide, etc.), you need a valid prescription from a licensed healthcare provider. This can be obtained through your primary care physician, a specialist, or a telemedicine platform. For the six HHS peptides, the prescription goes to a 503A compounding pharmacy. The prescription route provides the highest level of quality assurance since pharmaceutical-grade products undergo extensive manufacturing controls.
Legal Risks: What Can Actually Happen
For Individual Buyers
The practical legal risk for individuals buying peptides for personal use in the US is low. FDA’s published actions in 2025 and 2026 are warning letters to sellers. Customs seizures of international peptide shipments are possible. The bigger risk for a buyer is the product itself: nobody checks that an online vial contains what its label says, which is the reason HHS gave for its 2026 policy.
For Vendors
Vendors face real legal risk if they sell peptides for human use without approval, make therapeutic claims, or distribute HGH outside a medical prescription. FDA sent a batch of warning letters to peptide sellers on August 24, 2026, naming products such as retatrutide, semaglutide, SS-31, PT-141, tesamorelin and bacteriostatic water (FDA).
For Healthcare Providers
Physicians who prescribe FDA-approved peptides for off-label use are on solid legal ground — off-label prescribing is legal and common. Physicians who prescribe the six HHS peptides should confirm that the pharmacy meets every HHS condition, and should stay current with their state's medical board guidance.
Peptide Legality by Specific Compound
Since legal status can vary by compound, here's a detailed breakdown of the most popular peptides:
BPC-157
BPC-157 is not a controlled substance in the US and has no FDA approval. It sat in FDA’s Category 2 from September 2023 until April 22, 2026. Under HHS’s October 30, 2026 draft policy, a 503A pharmacy may compound BPC-157 acetate for injection, oral or topical use on a patient-specific prescription. Online vials sold for people remain unapproved drugs. In Australia it is Schedule 4 with possession without authority illegal; in sport it is banned under WADA S0.
TB-500 (Thymosin Beta-4)
TB-500 is the LKKTETQ fragment of thymosin beta-4. It has no FDA approval, sat in Category 2 from September 29, 2023 until April 22, 2026, and is now on HHS’s draft list for subcutaneous or intramuscular injection only. FDA had noted it “has not identified any human exposure data” for the fragment (FDA). It's banned by WADA for competitive athletes. The compound has been used extensively in veterinary medicine (particularly for equine treatment), which provides a broader safety and manufacturing base.
GH Secretagogues (Ipamorelin, CJC-1295, GHRP-2, etc.)
These have no FDA approval and are not on HHS’s list, so there is no legal US pharmacy route for them as of November 2026. Ipamorelin, GHRP-2 and GHRP-6 remain in FDA’s Category 2 for 503B outsourcing facilities. They are not scheduled as controlled substances, but they are all banned by WADA. MK-677 (ibutamoren), an oral GH secretagogue, stays in Category 2 for both 503A and 503B because of a heart failure signal, and is often sold alongside SARMs that FDA also treats as unapproved drugs.
Semaglutide and Other GLP-1 Agonists
Pharmaceutical semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) require a prescription. With both shortages declared over, FDA says 503B outsourcing facilities may not compound them from bulk, and 503A pharmacies may not regularly make copies of the approved products (FDA, April 1, 2026). Online “research” semaglutide or retatrutide is an unapproved drug in FDA’s view, and several 2025–2026 warning letters name GLP-1s. The molecule itself is not controlled — it's regulated as a drug product, which means the legal issue is about marketing and distribution, not possession.
Epitalon, GHK-Cu, and Other "Longevity" Peptides
Epitalon is on HHS’s draft list for injection in intermittent courses. GHK-Cu for injection was in Category 2 and is not on the HHS list; topical GHK-Cu is widely used in cosmetics, which is a separate rule set. Epitalon is not scheduled in any country we're aware of. GHK-Cu is a naturally occurring compound in the human body, which makes regulatory arguments against it weaker.
Importing Peptides: What You Need to Know
Domestic Shipping (Within the US)
Domestic shipments from US vendors do not pass through customs. Most vendors ship via USPS, FedEx, or UPS. Packages may require a signature depending on the vendor's policy. That convenience does not change the legal status of the product inside.
International Import to the US
Importing peptides from overseas vendors (China, India, Europe) into the US carries more risk. Customs can inspect packages, and some shipments are seized. HHS’s policy itself says it aims to move patients away from lab-labeled peptides made by foreign manufacturers that “pose a safety risk to US patients” (HHS). International purchases also carry quality concerns, as foreign manufacturers may not maintain the same standards as domestic suppliers.
Exporting from the US
US-based vendors can ship to many international destinations, but the receiving country's laws apply upon arrival. Australia, Canada and the UK all actively seize peptide imports. Check the destination country's import regulations before ordering internationally.
The Future of Peptide Regulation
The regulatory landscape for peptides is shifting, and several trends are worth watching:
Growing Mainstream Acceptance
As GLP-1 peptides like semaglutide have entered mainstream medicine, public awareness and acceptance of peptide therapy has increased dramatically. HHS’s October 2026 policy is the first federal step toward wider access. The next step is FDA rulemaking: HHS says “FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list” (Federal Register). Until a final rule exists, the policy can be revised or withdrawn.
State-Level Variations
Some states are moving to create their own peptide therapy frameworks. Florida, Texas, and several other states have taken steps to protect patient access to peptide therapy through compounding pharmacies, sometimes in direct response to federal restrictions. This state-level activity means the legal landscape may vary depending on where you live.
International Harmonization
The global peptide regulatory landscape remains fragmented. In 2026 the US widened access while Australia, Canada and the UK tightened enforcement. There's some movement toward harmonization, but meaningful international coordination is likely years away. For now, if you travel internationally with peptides, check the destination country's specific regulations; our guide to traveling with peptides covers airport rules.
Common Legal Misconceptions About Peptides
Misconception: "All peptides are illegal"
False. Dozens of peptides are FDA-approved prescription drugs, and six unapproved peptides now have a draft pharmacy route. Only a small number (primarily HGH and its direct analogs) carry criminal penalties. The confusion arises because many popular peptides are unapproved, which is not the same as illegal to own.
Misconception: "The FDA banned BPC-157"
Partially false. In September 2023 FDA put BPC-157 in Category 2, which pharmacies treated as a ban on compounding it. It was never a controlled substance, and possessing it is not a criminal offense in the US. It came off Category 2 on April 22, 2026, and HHS’s October 30, 2026 draft policy lets 503A pharmacies compound it on a prescription.
Misconception: "RFK Jr. made peptides legal again"
Partly true. The policy HHS published on October 30, 2026 is signed by Secretary Robert F. Kennedy Jr. But it covers six peptides, not 14 or 19, it is a draft enforcement promise rather than an approval, and it applies only to prescriptions filled by licensed pharmacies.
Misconception: "You need a prescription for all peptides"
Mostly true for legal access in the US. Approved peptides need a prescription, and so do compounded versions of the six HHS peptides. Peptides sold online without a prescription are being sold outside the law by the seller, which is why FDA keeps sending warning letters.
Misconception: "Buying peptides online is the same as buying drugs"
In FDA’s view, it is. When a website shows a peptide is meant for people, FDA treats it as an unapproved new drug, whatever the label says. The legal framework is still entirely different from purchasing controlled substances: the enforcement falls on the seller, and possession is not a crime.
Misconception: "If customs seizes my peptides, I'll be prosecuted"
Unlikely in the US. The typical outcome of a seized international shipment is confiscation and a notice. Australia is different: BPC-157 possession without authority is illegal there. Domestic shipments from US-based vendors don't involve customs at all.
Protecting Yourself: Best Practices
While the legal risks for individual peptide buyers are low in the US, here are practical steps to protect yourself:
- Use the prescription route where it exists: For the six HHS peptides, a 503A pharmacy prescription is now the legal option
- Keep documentation: Retain your order confirmation, COA, and payment records
- Don't resell: Buying for personal use is very different legally from reselling — don't distribute peptides to others
- Understand sports testing: If you compete in any tested sport, most peptides will cause a positive test
- Disclose to your doctor: If you're using peptides, telling your physician ensures they can properly interpret bloodwork and monitor your health
- Stay informed: Regulations change — follow primary sources such as the Federal Register and FDA, not forums
Frequently Asked Questions
References
- U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." FDA.gov, updated 2024.
- U.S. Food and Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A." FDA.gov, 2024.
- World Anti-Doping Agency. "The 2025 Prohibited List." WADA-AMA.org, effective January 1, 2025.
- Australian Therapeutic Goods Administration. "Scheduling of peptides and related compounds." TGA.gov.au, 2024.
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 in clinical trials." Curr Pharm Des. 2018;24(18):1990-2000. PMID: 29756568
- HHS. "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Federal Register FR Doc. 2026-22192, October 30, 2026; policy text with Appendix A and B; comments on docket HHS-OASH-2026-0496 close November 13, 2026.
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current April 22, 2026.
- FDA. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee; meeting notice Federal Register 2026-07361, April 16, 2026.
- FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, updated April 1, 2026.
- FDA warning letter to Peak Performance Peptides, MARCS-CMS 735127, August 24, 2026.
- Drugs@FDA (database): Ozempic NDA 209637; Wegovy NDA 215256; Mounjaro NDA 215866; Zepbound NDA 217806; Egrifta 022505; Vyleesi NDA 210557.
- 21 U.S.C. 333(e), prohibited distribution of human growth hormone (text).
- World Anti-Doping Agency. 2026 Prohibited List, in force January 1, 2026.
- TGA. Notice of final decisions to amend the Poisons Standard (BPC-157, Schedule 4), implementation June 1, 2024; safety advisory on unapproved peptide products, April 13, 2026.
- Health Canada. Think twice before injecting peptides bought online, April 9, 2026.
- MHRA. Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines, 29 May 2026.
Recommended Supplier
In StockShips from USAAscension Peptides
Third-party tested research peptides shipped from the US, with a batch COA on every product.
Exclusive 50% off — use code PEPTIDEDECK
Buy Related Peptides — 99%+ Purity
